Assessment of hepatic fibrosis in MAFLD: A new player in the evaluation of residual cardiovascular risk?

Autor:	Angelico F; Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy., Baratta F; Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University, Rome, Italy. Electronic address: francesco.baratta@uniroma1.it., Pastori D; Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University, Rome, Italy., Ben MD; Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University, Rome, Italy.
Jazyk:	angličtina
Zdroj:	Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver [Dig Liver Dis] 2021 Mar; Vol. 53 (3), pp. 383-384. Date of Electronic Publication: 2021 Jan 20.
DOI:	10.1016/j.dld.2020.12.123
Abstrakt:	Competing Interests: Conflict of interest Francesco Angelico: advisory board member and speaker fees from Mylan and Pharmextracta Francesco Baratta: None declared. Daniele Pastori: None declared Maria Del Ben: None declared.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect